Physician profile
Beth A Brey
NPI 1104914282
$2,458.10
in general payments reported to CMS, 2019-2025
26 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $516 · 2022: $526 · 2023: $422 · 2024: $552 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,316 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.65 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $308.57 | 2021-2025 | Farxiga, Wainua |
| Actelion Pharmaceuticals US, INC. | $253.14 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Novartis Pharmaceuticals Corporation | $212.03 | 2021-2024 | |
| Pfizer INC. | $193.87 | 2021-2025 | |
| Bridgebio Pharma, INC. | $186.74 | 2025 | Attruby |
| Amgen INC. | $185.03 | 2021-2023 | Repatha |
| Edwards Lifesciences Corporation | $135.98 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $131.63 | 2021-2023 | Bodyguardian, Watchman Access System |
| Impulse Dynamics (USA) INC. | $113.54 | 2023-2025 | Optimizer, Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.25 | 2021 | |
| Medtronic, INC. | $77.40 | 2024 | Corevalve Evolut R |
| Bayer Healthcare Pharmaceuticals INC. | $76.24 | 2022 | |
| Abiomed | $72.13 | 2024-2025 | Impella |
| Merck Sharp & Dohme LLC | $66.36 | 2021-2025 | Verquvo, Capvaxive |
| Novo Nordisk INC | $61.22 | 2024-2025 | Wegovy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $60.64 | 2021-2023 | |
| Amarin Pharma, INC. | $53.83 | 2021 | |
| Janssen Pharmaceuticals, INC | $31.16 | 2022-2024 | Xarelto |
| Esperion Therapeutics, INC. | $28.05 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.48 | 2022-2023 | Camzyos |
| Alnylam Pharmaceuticals INC. | $19.79 | 2025 | Onpattro |
| Philips North America LLC | $15.74 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $15.53 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $14.44 | 2024 | |
| Cvrx, INC. | $14.19 | 2024 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Brey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.